Texture_linecircles.png

Deverra is a clinical-stage biotechnology company developing universal donor cell therapy treatments to fight cancer and other life-threatening diseases.

 
Video_still.jpg

OUR
PLATFORM
TECHNOLOGY

InfoGraphic_OneToMany_v2.png

Allogeneic

Our platform technology uses sustainable, healthy cord blood cells to generate universal cell therapies, meaning no donor-patient matching is needed

Versatile

Our platform is capable of generating many distinct cell types resulting in a diverse pipeline of cell therapies for multiple indications.

Accessible

Our scalable manufacturing and effective cryopreservation enables delivery of

ready-made therapies

for immediate,

on-demand use

Experienced

We have 20+ years of experience in developing allogeneic off-the-shelf therapies based on federally funded research and across five clinical trials to date

OUR THREE
LEADING PROGRAMS

Cell_Progenitor.png

01

Stem and Progenitor Cell

We provide treatment options for newly diagnosed AML patients with our hematopoietic stem & progenitor cell immunotherapy

Dilanubicel, our lead product, has been evaluated in a global phase 2 randomized controlled trial in patients with newly diagnosed AML.  Data from this study demonstrated a statistically significant increase in remission rates in patients who received dilanubicel as an adjuvant to standard of care chemotherapy when compared to patients who received standard of care chemotherapy alone.

Cell_NK.png

02

Natural Killer Cell

We generate natural killer (NK) cells that are used to fight cancer and to boost immunity against viral infections.

DVX201, our NK cell product, is in clinical trials to treat patients with relapsed/refractory AML or high risk MDS and patients hospitalized with COVID-19. Our goal is to create a family of NK cell therapies that also include NK cells engineered to target specific cancers (CAR-NKs).

Cell_Myeloid.png

03

Myeloid Cell

We aim to target solid tumors using the patient’s own immune system activated by our myeloid cell product

Our goal is to develop engineered monocyte/macrophage therapies to treat patients with solid tumors, alone or in combination with other cell therapy products generated off our platform.

We pioneered the development of cell therapies accessible for all patients with no matching required

Diagram_3BubbleHistory_v3.png
Texture_shootinglines.png

OUR CLINICAL TRIALS

Home_ClinicalTrials_v1.png

JOIN US

We are actively seeking innovative, collaborative, and dedicated team members. Join our highly-skilled & diverse team of professionals dedicated to working on ground-breaking treatments in a workplace culture inclusive for all.